MedTrace Logo

NasoNeb Delivery of an Intranasal Steroid

NCT01270256 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2014-07-25

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to see if a nasal steroid drug delivered to the nose with the NasoNeb™ inhaler improves the symptoms of people with perennial allergic rhinitis (year round allergy symptoms).

Conditions

  • Perennial Allergic Rhinitis

Interventions

DRUG

Budesonide

Pulmicort Respules at a dose of 0.25 mg. delivered intranasally via NasoNeb nebulizer once daily

DRUG

Placebo

Placebo delivered intranasally via NasoNeb nebulizer once daily

Sponsors & Collaborators

  • MedInvent, LLC

    collaborator UNKNOWN

  • University of Chicago

    lead OTHER

Principal Investigators

  • Robert M Naclerio, MD · University of Chicago

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2012-07-31
Completion
2012-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01270256 on ClinicalTrials.gov